文献速递治疗药物监测与药物基因组学

首个口服靶向抗肿瘤药国际质控计划结果

Results of the first international quality control programme for oral targeted oncolytics.
PubMed 文献 · Br J Clin Pharmacol · 2023-10-13

该研究开展了一次性国际质控计划,评估实验室检测口服靶向抗肿瘤药浓度的性能。

要点

  • 80.7%的测量在预设准确度范围(85%-115%)内
  • 伊马替尼定量表现最佳,去乙基舒尼替尼最差
  • 药物种类和实验室影响绝对不准确度(p<0.001)

核心结论

  • 首次口服靶向抗肿瘤药国际质控计划中,较高比例测量在预设准确度范围内。
  • 用于剂量优化的检测方法交叉验证可保障性能并保护患者免于错误建议。

研究设计与样本

  • 一次性国际质控计划,参与实验室收到含低、中、高浓度九种药物的血浆样本,需在发货后五周内报告结果。
  • 准确度可接受定义为测量值在称量参考浓度的85%-115%范围内。

主要发现

  • 总体80.7%的测量在预设可接受准确度范围内。
  • 伊马替尼定量表现最佳,中位绝对不准确度4.0%(IQR 1.8%-6.5%)。
  • 去乙基舒尼替尼定量表现最差,中位绝对不准确度15.5%(IQR 8.8%-34.9%)。
  • 药物种类和实验室影响绝对不准确度(F=16.4;p<0.001和F=35.5;p<0.001)。

关键数值与推荐

  • 准确度可接受范围:测量值在称量参考浓度的85%-115%内。

临床怎么用

  • 临床使用口服靶向抗肿瘤药TDM结果时,应关注检测方法的准确度和交叉验证情况。
  • 对去乙基舒尼替尼等代谢物定量需注意内标选择和光致异构化影响。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: With the rising number of oral targeted oncolytics and growing awareness of the benefits of therapeutic drug monitoring (TDM) within the field of oncology, it is expected that the requests for quantifying concentrations of these drugs will increase. It is important to (cross-)validate available assays and ensure its quality, as results may lead to altered dosing recommendations. Therefore, we aimed to evaluate the performance of laboratories measuring concentrations of targeted oral oncolytics in a one-time international quality control (QC) programme. METHODS: Participating laboratories received a set of plasma samples containing low, medium and high concentrations of imatinib, sunitinib, desethylsunitinib, pazopanib, cabozantinib, olaparib, enzalutamide, desmethylenzalutamide and abiraterone, with the request to report their results back within five weeks after shipment. Accuracy was defined acceptable if measurements where within 85%-115% from the weighed-in reference concentrations. Besides descriptive statistics, an exploratory ANOVA was performed. RESULTS: Seventeen laboratories from six countries reported 243 results. Overall, 80.7% of all measurements were within the predefined range of acceptable accuracy. Laboratories performed best in quantifying imatinib and poorest in quantifying desethylsunitinib (median absolute inaccuracy respectively 4.0% (interquartile range (IQR) 1.8%-6.5%) and 15.5% (IQR 8.8%-34.9%)). The poorest performance of desethylsunitinib might be caused by using the stable-isotope-labelled sunitinib instead of desethylsunitinib as an internal standard, or due to the light-induced cis(Z)/trans(E) isomerization of (desethyl)sunitinib. Overall, drug substance and performing laboratory seemed to influence the absolute inaccuracy (F = 16.4; p < 0.001 and F = 35.5; p < 0.001, respectively). CONCLUSION: Considering this is the first evaluation of an international QC programme for oral targeted oncolytics, an impressive high percentage of measurements were within the predefined range of accuracy. Cross-validation of assays that are used for dose optimization of oncolytics will secure the performance and will protect patients from incorrect advices.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Giraud EL, Te Brake LMH, van den Hombergh ECA, et al. Results of the first international quality control programme for oral targeted oncolytics. Br J Clin Pharmacol. 2023. PMID: 37776845. doi:10.1111/bcp.15918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。